Surgery vs semaglutide for heart outcomes

A study published in Endocrine Practice on 11 August 2026 puts the two main options for treating obesity side by side. One is semaglutide, a GLP-1 receptor agonist, meaning a drug that mimics the gut hormone GLP-1 to reduce appetite and slow digestion. The other is metabolic and bariatric surgery, operations such as sleeve gastrectomy and Roux-en-Y gastric bypass that permanently resize or reroute the stomach and small intestine^[1]. The question the authors ask is direct: for an adult with obesity, which path is followed by fewer serious heart and blood vessel events?

What the new study found

The research team used TriNetX, a large network of US electronic health records, to identify adults with obesity who either started semaglutide or underwent one of the two operations between January 2018 and January 2025^[1]. They split patients by whether they had type 2 diabetes, then used propensity score matching, a statistical method that pairs patients with similar recorded characteristics so the two groups start out looking alike on paper^[1]. After matching, each treatment arm held 11,466 patients without diabetes and 7,327 patients with diabetes^[1].

The primary outcome was a composite, a single bucket combining coronary events, cerebrovascular events such as strokes, heart failure, and cardiac arrest, tracked for up to five years^[1]. Among patients without diabetes, that composite occurred in 4.4% of the surgery group and 6.6% of the semaglutide group, a hazard ratio of 0.402 with a 95% confidence interval of 0.356 to 0.454^[1]. A hazard ratio below 1 means fewer events over time in the first group, so 0.402 reads as roughly 60% lower relative risk after surgery.

Among patients with type 2 diabetes the absolute gap was wider: 9.0% after surgery versus 14.6% on semaglutide, hazard ratio 0.421 with a 95% confidence interval of 0.381 to 0.465^[1]. The largest relative difference was heart failure, with hazard ratios of 0.293 in patients without diabetes and 0.346 in patients with diabetes^[1]. The authors report that subgroup and sensitivity analyses, which varied the follow-up window, encounter requirements, and how strictly semaglutide use was defined through refill records, pointed in the same direction^[1].

What semaglutide has already proven for the heart

None of this erases what semaglutide has shown in a randomized trial. The SELECT trial enrolled 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes, and assigned them to once-weekly semaglutide 2.4 mg, the labeled weight-management dose, or placebo^[2]. Over a mean follow-up of 39.8 months, the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke occurred in 6.5% of the semaglutide group against 8.0% on placebo, a hazard ratio of 0.80^[2].

That result is why the US prescribing information for Wegovy carries an indication to reduce the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight^[4]. The new study does not contradict any of this. SELECT compared semaglutide with placebo; the Endocrine Practice analysis compares semaglutide with surgery. They answer different questions, and our semaglutide evidence page tracks both lines of evidence as they develop.

Surgery has a much longer evidence trail

The surgery side of the ledger rests on decades of follow-up. The Swedish Obese Subjects study, a nonrandomized prospective comparison, followed 2,010 patients who underwent bariatric surgery against 2,037 matched controls receiving usual care, for a median of 14.7 years^[3]. Surgery was associated with fewer cardiovascular deaths (adjusted hazard ratio 0.47) and fewer first heart attacks or strokes (adjusted hazard ratio 0.67)^[3]. The new TriNetX analysis sits in line with that older signal and extends it to a direct comparison against the most widely prescribed obesity medicine, semaglutide.

Why this is not a settled verdict

The Endocrine Practice study is observational. Nobody was randomized. Patients who have bariatric surgery differ from patients who receive a prescription in ways a records database only partly captures: surgical candidates are screened, insured for the procedure, and well enough for an operation, while the semaglutide group includes everyone who simply started the drug, whether or not they stayed on it^[1]. Propensity matching adjusts for recorded differences, not unrecorded ones, so residual confounding, meaning leftover differences between the groups, can push the hazard ratios in either direction.

There is also a time problem. The study window runs from 2018, years before the 2.4 mg weight-management dose came into wide use, so much of the semaglutide exposure in the data reflects doses approved for diabetes and patients who stopped within months, while surgical patients carry a permanent intervention from day one^[1]. The authors themselves frame the findings as real-world comparative evidence to inform individual discussions of surgical and pharmacologic options, not as a final ranking^[1]. A randomized head-to-head trial of drug versus surgery on cardiovascular outcomes does not yet exist.

What this means if you are weighing the two

For a reader choosing between a weekly injection and an operation, the honest reading is this. In one large records dataset, surgery carried the stronger association with lower cardiovascular risk, in people with and without type 2 diabetes^[1]. Semaglutide, meanwhile, holds randomized-trial proof of cardiovascular benefit against placebo and a US label indication to match^[2][4]. The practical differences run in both directions: surgery is one irreversible procedure with operative risk and a long recovery, while semaglutide avoids the operating room but is prescribed as an ongoing once-weekly treatment^[4].

Cost, eligibility, other medical conditions, and personal tolerance for risk all sit inside that choice, and an observational study cannot make it for anyone. Our semaglutide access and regulation notes track what coverage looks like in practice, since that decides as much as any hazard ratio.

This article is educational and is not medical advice. Decisions between medication and bariatric surgery belong with a qualified healthcare provider who knows your history.